Company Description
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases.
Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Michael Myers |
Contact Details
Address: 42127 Pleasant Forest Court Ashburn, Virginia 20148-7349 United States | |
| Phone | 703 980 4182 |
| Website | quoinpharma.com |
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L102 |
| ISIN Number | US74907L3006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
| Gordon Bruce Dunn J.D. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 4, 2025 | 8-K | Current Report |
| Jan 28, 2025 | SCHEDULE 13D/A | Filing |
| Jan 28, 2025 | SCHEDULE 13D/A | Filing |
| Jan 23, 2025 | 8-K | Current Report |